SDH reports grants and contracts from Shionogi and support for attending meetings or travel from DAVA Oncology. SK reports stock options from Iylon, Lutris, MolecularMatch, and Navire (none of these companies operate in areas related to the topic discussed in this Comment); consulting fees from AbbVie, Amal Therapeutics, AstraZeneca-MedImmune, Bayer Health, Bicara Therapeutics, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Flame Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapeutics, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapeutics, Servier, and Xilis; and grants and contracts from Amgen, Array BioPharma, Biocartis, Daiichi Sankyo, EMD Serono, Genentech-Roche, Guardant Health, Lilly, MedImmune, Novartis, and Sanofi.